Venetoclax - AbbVie/Genentech
Alternative Names: A-1195425.0; ABT 0199; ABT 199; GDC-0199; RG-7601; RO-5537382; Venclexta; VENCLYXTO; VenclyxtoLatest Information Update: 28 Aug 2025
At a glance
- Originator Abbott Laboratories; Genentech; Walter and Eliza Hall Institute of Medical Research
- Developer AbbVie; Celgene Corporation; Dana-Farber Cancer Institute; Emory University; Genentech; Janssen Research & Development; M. D. Anderson Cancer Center; Merck & Co; Nantes University Hospital; National Cancer Institute (USA); Nordic Lymphoma Group; Pharmacyclics; Roche; Syros Pharmaceuticals; University Health Network
- Class Antineoplastics; Benzamides; Heterocyclic bicyclo compounds; Piperazines; Pyrans; Pyridines; Pyrroles; Small molecules; Sulfonamides
- Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic lymphocytic leukaemia
- Registered Acute myeloid leukaemia
- Phase III Mantle-cell lymphoma
- Phase II Breast cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; T-cell prolymphocytic leukaemia; Waldenstrom's macroglobulinaemia
- Phase I/II Chronic myelomonocytic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer
- No development reported B-cell lymphoma; Blastic plasmacytoid dendritic cell neoplasm; Cancer; Haematological malignancies; Myelodysplastic syndromes; Non-small cell lung cancer; Small cell lung cancer; Systemic lupus erythematosus
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for phase-I development in Haematological-malignancies(Combination therapy, Late-stage disease) in USA (PO, Tablet)
- 30 Jul 2025 AbbVie files sNDA for treatment of patients with Chronic lymphocytic leukemia in USA
- 24 Jul 2025 Discontinued - Phase-III for Myelodysplastic syndromes (Combination therapy, First-line therapy, Newly diagnosed) in Turkey, Spain, Puerto Rico, Netherlands, Japan, Czech Republic, Belgium, Italy, Australia, France, USA (PO)